Log In
Print
BCIQ
Print
Print this Print this
 

StarGen

  Manage Alerts
Collapse Summary General Information
Company Oxford BioMedica plc
DescriptionLentiVector-based gene therapy expressing a corrected version of ATP-binding cassette sub-family A member 4 (ABCA4; ABCR)
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Lentivirus
Latest Stage of DevelopmentPhase I/II
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat Stargardt's disease
Regulatory Designation
Partner Sanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$26.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today